Patients with HFpEF should receive a SGLT2 inhibitor, based on the demonstrated benefits of empagliflozin and sotagliflozin in HFpEF.123 ARNI and RAS inhibitors may be appropriate for select patients with less than normal ejection fraction.158,165 Likewise, the nonsteroidal MRA finerenone may be considered for patients with HFpEF, T2D, and CKD (see Section 2.3.5. The gene discussed is SLC5A2; the disease is chronic kidney disease.